There is concern about side effects, however, the development of chloramphenicol resistant H influenzae type b and, more recently, the proposed withdrawal from the local market of the oral chloramphenicol suspension. Severe side effects are well recognised, but rare; the risk of fatal aplastic anaemia is estimated to be one in 20 000.7 Chloramphenicol resistance is also uncommon in this community. Despite this long and successful experience,3 prescribing patterns for antibiotics are apparently changing as 14/24 (58%) patients excluded from this study had been given third generation cephalosporins before admission to this hospital.
Five days has been the standard duration of chloramphenicol treatment of epiglottitis in Australia. There is little but historical precedent to support this. Epiglottitis is an invasive H influenzae type b infection and 85% of patients in this study had positive blood cultures. Resolution of illness occurs quickly with a rapid defervescence of temperature, a short period of intubation, and a mean length of hospital stay of only 50 hours. H influenzae type b disease at other sites, relapse, or recurrence is rare. These are compelling reasons to reconsider the appropriate duration of treatment for this infection.
Ceftriaxone is a third generation cephalosporin with a long elimination half life, excellent tissue penetration, and proved activity against H influenzae type b.i Knight et al reported the successful treatment of epiglottitis in seven children using a single dose of 100 mg/kg ceftriaxone once a day for five days.4 A five day course of ceftriaxone is an expensive alternative to chloramphenicol and the same group of workers have reported the successful treatment of 11 patients with a single dose of 100 mg/kg ceftriaxone once a day for three days.9 Both were uncontrolled studies.
This study shows that two doses of ceftriaxone were efficacious in the treatment of 28 patients with epiglottitis, with no relapses, recurrences, or side effects. Although this study lacked the power to address the question of efficacy, it was sufficiently powerful to exclude important differences in the rate of recovery from epiglottitis. We did not observe significant differences between patients who received ceftriaxone and those who received chloramphenicol for any of the trial endpoints.
Criticism of the use of cephalosporins in invasive disease has been in part because of the acquisition cost of the drug. The frequency and rate of administration also has a significant effect on total cost, however. Although the acquisition cost of two doses of ceftriaxone is higher than five days of chloramphenicol (A$56 v A$35), the overall costs when administration costs such as nursing time and Health and Medical Research Council (Australia), among-other authorities, recommend that, ifthe contact group includes a child under the age of 4 years, the whole group should receive rifampicin prophylaxis to eradicate throat carriage of H influenzae type b.12 A study of rifampicin prophylaxis in patients with H influenzae type b disease at this hospital showed that 34% of patients treated with chloramphenicol but not given rifampicin had positive throat swabs at follow up, compared with only 7% in those given rifampicin prophylaxis. In families in which all members received rifampicin, only 3% of children were colonised with H influenzae type b at follow up. 5 Despite the significantly increased risk of H influenzae type b disease among close contacts, recognised disease in close contacts accounts for only 1-2% of cases, and rifampicin prophylaxis, as recommended, is time consuming and costly. A review of prescribing habits for rifampicin prophylaxis at this institution showed that rifampicin was prescribed correctly in only 59% of family members including the index case, and was not prescribed in 34% of families in whom it was indicated according to the current recommendations. In conclusion, short term treatment with ceftriaxone was used successfully in 28 patients with epiglottitis. It was simple to administer, well tolerated, cost effective, and overcame the need for drug treatment after discharge. It is an efficacious and safe alternative to five days of treatment with chloramphenicol.
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